Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 107

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 107
---
 and teaching purposes
provided that any results from such efforts shall be the sole property of Yissum and shall be exclusively licensed to LipoVation under
the agreement. If Yissum desires to license or divest any of the intellectual property rights, the Company has the right of first negotiation
with respect to such rights. Under the license agreement, we are responsible for, and are required to exert, reasonable commercial efforts
to carry out the development, regulatory, manufacturing and marketing work necessary to develop and commercialize products under the
agreement in accordance with a specified development plan.

We paid Yissum a $35,000 license fee, and
on each anniversary date of the agreement we owe pay Yissum an annual license maintenance fee of $35,000. The license fee is credited
against royalties due to Yissum, and if we paid Yissum $100,000 during the previous year for research activities the license fee for
said year is not due. Pursuant to the terms of the license agreement, we owe Yissum $150,000 upon the first patient being enrolled in
a Phase I clinical trial; $300,000 upon the first patient in a Phase II clinical trial; $450,000 upon the first patient being enrolled
in a Phase III clinical trial; and $600,000 upon the earlier of the first commercial sale in either Europe or the U.S.

Royalties will be payable to Yissum at the
rate of 3% of sales of any products which use, exploit or incorporate technology covered by the Licensed Patents (“Net Sales”).

We also have to pay Yissum 13% of any proceeds
we receive from sublicensees other than royalties from a sublicensee.

The Licensed Patents expire, if not earlier terminated
pursuant to the provisions of the Yissum Agreement, on a country-by-country, product-by-product basis, upon the later of: (i) the date
of expiration in such country of the last to expire Licensed Patent included in the Licensed Technology; (ii) the date of expiration of
any exclusivity on the product granted by a regulatory or government body in such country; or (iii) the end of a period of twenty (20)
years from the date of the first commercial sale in such country. Should the periods referred to in items (i) or (ii) above expire in
a particular country prior to the period referred to in item (iii), above, the license in that country